All these results illustrated the pro-tumorigenic effects of RNF220/USP22/BMI1 signal pathway on proliferation and stemness of colorectal cancer, providing novel insights into RNF220 as clinical therapeutic candidates for future drug design and development targeting colorectal cancer. This evidence concerns the gene USP22 and colorectal cancer.